The study looks at adults who may have narrowing (called steno-occlusive disease) in the major arteries that supply the head, neck, arms, legs, abdomen, or kidneys, such as the carotid and vertebrobasilar vessels, other peripheral arteries, and abdominal/renal arteries. Two contrast agents are being compared: the new agent gadopiclenol and the established agent gadoterate meglumine. Both are given by a quick intravenous injection during a scan called Magnetic Resonance Angiography, which uses magnetic fields to create detailed pictures of blood vessels.
The purpose of the study is to show that the new agent works at least as well as the standard agent in finding and ruling out disease, measured by how often it correctly identifies problems (sensitivity) and how often it correctly shows no problem (specificity) when compared with reference tests such as Computed Tomography Angiography or Intra-arterial Digital Subtraction Angiography. Participants will receive one of the agents in a randomized, double‑blind, crossover design, meaning they will have two scanning sessions, each with a different agent, while neither the participants nor the doctors know which is used at each visit. The study follows a set schedule of visits and scans, and safety checks are performed after each injection.
Czechia 
France 
Germany 
Hungary 
Italy 
Poland 
Spain 
